Black Diamond Therapeutics, Inc.

NasdaqGS:BDTX Rapport sur les actions

Capitalisation boursière : US$137.5m

Black Diamond Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG Black Diamond Therapeutics est Mark Velleca, nommé en Sep2023, a un mandat de 1.17 ans. La rémunération annuelle totale est $ 3.39M, composée du salaire de 5.3% et des bonus 94.7%, y compris les actions et options de la société. détient directement 0.082% des actions de la société, d'une valeur de $ 113.05K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.6 ans et 4.4 ans.

Informations clés

Mark Velleca

Directeur général

US$3.4m

Rémunération totale

Pourcentage du salaire du PDG5.3%
Durée du mandat du directeur général1.2yrs
Propriété du PDG0.08%
Durée moyenne d'occupation des postes de direction2.6yrs
Durée moyenne du mandat des membres du conseil d'administration4.4yrs

Mises à jour récentes de la gestion

Recent updates

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Oct 30
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 08

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 27

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 21
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 31
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 12

Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Oct 26
Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

May 05
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Jan 16
We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Oct 02
Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?

Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

Jul 02
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?

We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

Jan 16
We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully

We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Jun 11
We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely

Black Diamond Therapeutics EPS misses by $0.16

May 07

We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

Feb 26
We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate

What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Jan 05
What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition

Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Dec 01
Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?

Black Diamond nominates development candidate for glioblastoma program

Nov 20

Black Diamond Therapeutics EPS beats by $0.02

Nov 10

Black Diamond Therapeutics: One To Watch In Precision Oncology Space

Oct 23

Analyse de la rémunération des PDG

Comment la rémunération de Mark Velleca a-t-elle évolué par rapport aux bénéfices de Black Diamond Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$73m

Jun 30 2024n/an/a

-US$81m

Mar 31 2024n/an/a

-US$80m

Dec 31 2023US$3mUS$180k

-US$82m

Sep 30 2023n/an/a

-US$84m

Jun 30 2023n/an/a

-US$83m

Mar 31 2023n/an/a

-US$87m

Dec 31 2022US$65kn/a

-US$91m

Sep 30 2022n/an/a

-US$96m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$121m

Dec 31 2021US$204kn/a

-US$126m

Rémunération vs marché: La rémunération totale de Mark ($USD 3.39M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 652.28K ).

Rémunération et revenus: La rémunération de Mark a augmenté alors que l'entreprise n'est pas rentable.


PDG

Mark Velleca (60 yo)

1.2yrs

Titularisation

US$3,387,383

Compensation

Dr. Mark A. Velleca, M. D., Ph. D., serves as President & Chief Executive Officer at Black Diamond Therapeutics, Inc. since September 16, 2023 and serves as its Chairman since December 2022. He has been an...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Mark Velleca
CEO, President & Chairman1.2yrsUS$3.39m0.082%
$ 113.1k
David M. Epstein
Co-Founder & Directorno dataUS$2.02m1.61%
$ 2.2m
Fang Ni
Advisorless than a yearUS$1.49m0.23%
$ 311.8k
Sergey Yurasov
Chief Medical Officer2.4yrsUS$1.23m0%
$ 0
Elizabeth Buck
Co-Founder & Chief Scientific Officer3.3yrsUS$347.30kpas de données
Erika Jones
Principal Financial Officer3.8yrspas de donnéespas de données
Brent Hatzis-Schoch
COO & General Counsel5.5yrsUS$911.23k0.015%
$ 20.4k
Elizabeth Montgomery
Chief People Officer2.8yrspas de donnéespas de données
Melanie Morrison
Chief Development Officer2yrspas de donnéespas de données

2.6yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe de direction de BDTX est considérée comme expérimentée (ancienneté moyenne 2.6 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Mark Velleca
CEO, President & Chairman3.3yrsUS$3.39m0.082%
$ 113.1k
David M. Epstein
Co-Founder & Director8.2yrsUS$2.02m1.61%
$ 2.2m
Ali Behbahani
Independent Director5.9yrsUS$68.14k0.10%
$ 139.9k
Garry Menzel
Independent Director7.7yrsUS$75.35k0.14%
$ 186.3k
Kapil Dhingra
Independent Director3.8yrsUS$109.35k0.018%
$ 24.3k
Samarth Kulkarni
Lead Independent Director5yrsUS$59.35k0%
$ 0
Prakash Raman
Independent Directorless than a yearpas de données0.0088%
$ 12.1k
Shannon Campbell
Independent Directorless than a yearpas de données0.0077%
$ 10.6k

4.4yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de BDTX sont considérés comme expérimentés (ancienneté moyenne 4.4 ans).